Skip to main content

Table 2 Dose of lanthanum carbonate at the end of the dose-titration phase; safety set

From: Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients

Dose, mg/day Dose-titration phase (n= 39) Parallel-group phase
Lanthanum carbonate (n= 10) Placebo (n= 11)
375 5 (12.8) 1 (10.0) 0 (0.0)
750 11 (28.2) 3 (30.0) 4 (36.4)
1500 14 (35.9) 3 (30.0) 4 (36.4)
2250 9 (23.1) 3 (30.0) 3 (27.3)
  1. Data are presented as n (%).